Amarin (NASDAQ:AMRN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Amarin (NASDAQ:AMRN) in a report released on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Amarin Trading Up 1.8 %

Shares of NASDAQ:AMRN opened at $0.45 on Monday. The stock has a market capitalization of $184.02 million, a PE ratio of -4.98 and a beta of 1.82. The firm has a 50 day moving average of $0.53 and a 200-day moving average of $0.54. Amarin has a 12 month low of $0.35 and a 12 month high of $1.11.

Shares of Amarin are scheduled to reverse split on the morning of Friday, April 11th. The 1-20 reverse split was announced on Wednesday, March 12th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, April 10th.

Amarin (NASDAQ:AMRN) last announced its quarterly earnings results on Wednesday, March 12th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The company had revenue of $62.31 million for the quarter, compared to the consensus estimate of $32.37 million. Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%. On average, research analysts predict that Amarin will post -0.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Amarin

Institutional investors and hedge funds have recently bought and sold shares of the company. Arkfeld Wealth Strategies L.L.C. lifted its holdings in shares of Amarin by 52.6% during the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 20,000 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of Amarin in the 4th quarter valued at about $36,000. Generation Capital Management LLC acquired a new stake in shares of Amarin in the fourth quarter valued at about $50,000. Stonepine Capital Management LLC bought a new position in shares of Amarin during the fourth quarter worth about $55,000. Finally, New York State Common Retirement Fund bought a new stake in Amarin in the fourth quarter valued at approximately $68,000. Institutional investors and hedge funds own 22.25% of the company’s stock.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.